Citius Oncology Inc
CTOR
Company Profile
Business description
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
Contact
11 Commerce Drive
First Floor
CranfordNY07016
USAT: +1 908 967-6677
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 September 2026
Employees
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.60 | 54.00 | -0.60% |
| CAC 40 | 8,424.08 | 38.59 | 0.46% |
| DAX 40 | 24,883.52 | 143.16 | 0.58% |
| Dow JONES (US) | 52,086.83 | 237.93 | 0.46% |
| FTSE 100 | 10,529.69 | 68.06 | 0.65% |
| HKSE | 23,076.91 | 335.27 | -1.43% |
| NASDAQ | 25,276.66 | 199.98 | -0.78% |
| Nikkei 225 | 72,366.34 | 3,191.38 | 4.61% |
| NZX 50 Index | 13,493.05 | 92.39 | 0.69% |
| S&P 500 | 7,348.00 | 10.22 | -0.14% |
| S&P/ASX 200 | 8,748.70 | 51.90 | -0.59% |
| SSE Composite Index | 4,120.28 | 9.47 | 0.23% |